Normal layoutMedium LayoutLarge Layout Normal TextMedium TextLarge Text Search Site   
Home Me Family Gallery Research Events Articles Downloads Forums Contact
Me Login  | Register
CURRICULUM VITAE (updated on June 01 2008)
 
NAME:                      Salih Sanlioglu, V.M.D, Ph.D.
 
ADDRESS:                Human Gene Therapy Unit of Akdeniz University Faculty of Medicine, B Block, 1st floor, Campus, Antalya, 07070, Turkey
PHONE:                    Work: 90 (242) 249-6157/ 249-6166 Fax: 90 (242) 227-4482
 
E-mail:                       ssanlioglu@gmail.com
 
Web:                          http://www.salihsanlioglu.com  ;   http://www.trsgt.org
 
PROFESSIONAL EXPERIENCE:
 
2008- Present Professor, Department of Medical Biology and Genetics, Akdeniz University, College of Medicine; Topic of interest: Personalized Medicine.
 
2002- Present Director of the Human Gene Therapy Unit of Akdeniz University, Faculty of Medicine; Topic of interest: Development of novel gene therapy approaches against acquired human diseases such as cancer (prostate, lung, breast etc), diabetes and rheumatoid arthritis etc.
 
2002-2007       Associate Professor, Department of Medical Biology and Genetics, Akdeniz University, College of Medicine; Topic of interest: Molecular diagnostics.
 
2001-2002       Assistant Professor, Department of Medical Biology and Genetics, Akdeniz University, College of Medicine and The Gene Therapy Center, Department of Internal Medicine, University of Iowa;  Topic of interest: Adenovirus mediated gene therapy approach for sepsis.
 
1998- 2001      Research Fellow, Gene Therapy Center and Department of Internal Medicine, College of Medicine, University of Iowa; Topic of interest: Molecular mechanism of AAV transduction and implications for human gene therapy.
 
1997-1998             Postdoctoral Associate, Institute for Human Gene Therapy, College of
Medicine; University of Pennsylvania Topic of interest: AAV mediated gene therapy for liver.
 
1992-1996       Graduate Teaching and Research Associate, College of Medicine, Ohio State University; Topic of interest: İn vivo gene transfer and the disruption of cerebellar patterning.
 
1990-1992       National Scholar, Children’s Hospital, Ohio State University. Topic of interest: Molecular cloning and characterization of two novel human genes.
 
1988-1990              Veterinary Medical Doctor (V.M.D.), Department of Microbiology, Immunology and Infectious Diseases, University of Selcuk.
 
EDUCATION:
 
1992-1996       Ph.D. Graduate Studies in Molecular, Cellular Biology and Genetics, College of Medicine, the Ohio State University Thesis Title: Ectopic Engrailed-2 expression through in vivo gene transfer and its consequence on cerebellar patterning. Journal of Neuroscience 18(5):1763-73 1998.
 
1990-1992       M.S. Graduate Studies in Molecular, Cellular Biology and Genetics, College of Medicine, Ohio State University Thesis Title: Molecular cloning and characterization of two novel human genes (RP1 and RP2) located upstream of complement C4A and C4B in the HLA Class III region. Journal of Biological Chemistry 269(11):8466-76, 1994.
 
1988-1990       Graduate Studies in Microbiology and Immune-Serology at the Institute of Health, University of Selcuk.
 
1983-1988       Veterinary Medical Doctor (V.M.D), College of Veterinary Medicine, University of Selcuk
 
 
PUBLICATIONS (All ISI Indexed):
 
  1. Molecular mechanisms of death ligand-mediated immune modulation: A gene therapy model to prolong islet survival in type 1 diabetes. Sanlioglu AD, Griffith TS, Omer A, Dirice E, Sari R, Altunbas HA, Balci MK, and Sanlioglu S. J Cell Biochem 2008 June 1; 104(3):710-720.
 
  1. High levels of endogenous TRAIL expression correlate with increased cell death in human pancreas. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Balcı MK, Omer A, Griffith TS and Sanlioglu S. Pancreas 2008 May; 36(4):385-393.
 
  1. TRAIL-R4 decoy receptor gene expression is correlated with high Gleason scores, PSA recurrence and decreased survival in patients with prostate carcinoma. Koksal IT, Sanlioglu AD, Karacay B,Griffith TS and Sanlioglu S. Urologic Oncology 2008 Mar-Apr; 26(2):158-165.
 
  1. DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells. Sanlioglu AD, Karacay B,Koksal IT, Griffith TS and Sanlioglu S. Cancer Gene Therapy.2007 Dec; 14(12):976-984.
 
  1. Corneal protein nitration in experimental uveitis. Aslan M, Yucel I, Akar Y, Yücel G, Ciftcioglu MA and Sanlioglu S. Exp Biol Med (Maywood).2007 Nov; 232(10): 1308-1313.
 
  1. TRAIL death receptor-4 (DR4) expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Sanlioglu AD, Korcum AF, Pestereli E, Erdogan G, Karaveli S, Savas B, Griffith TS and Sanlioglu S. Int J Radiat Oncol Biol Phys. 2007 Nov; 69(3): 716-723.
 
  1. Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis.Terzioglu E, Bisgin A, Sanlioglu AD, Ulker M, Yazisiz V, Tuzuner S, and Sanlioglu S. Rheumatology (Oxford). 2007 May; 46(5): 783-789.
 
  1. A DcR2 siRNA strategy employing three different siRNA constructs in combination defeats adenovirus transferred TRAIL resistance in lung cancer cells. Aydin C, Sanlioglu AD, Karacay B, Ozbilim G, Dertsiz L, Ozbudak O, Akdis CA and Sanlioglu S. Human Gene Therapy. 2007 Jan; 18: 39-50.
 
  1. Dajani R, Sanlioglu S, Zhang Y, Li Q, Monick MM, Lazartigues E, Eggleston T, Davisson RL, Hunninghake GH, Engelhardt JF.Pleiotropic Functions of TNF alpha Determine Distinct IKK beta-Dependent Hepatocellular Fates in Response to LPS. Am J Physiol Gastrointest Liver Physiol. 2007 Jan; 292(1): G242-252.
 
  1. Differential expression of TRAIL and its receptors in benign and malignant prostate tissues. Sanlioglu AD, Koksal IT, Ciftcioglu MA, Baykara M, Luleci G and Sanlioglu S. Journal of Urology. 2007 Jan; 177(1): 359-364.
 
  1. Nitrotyrosine Formation and Apoptosis in Rat Models of Ocular Injury. Aslan M, Yucel I, Akar Y, Yücel G, Çiftçioglu MA and Sanlioglu S. Free Radical Research. 2006 Feb; 40(2): 147-153.
 
12. Adenovirus mediated IKKbKA expression sensitizes prostate carcinoma cells to TRAIL induced apoptosis. Sanlioglu AD, Koksal IT, Karacay B, Baykara M, Luleci G and Sanlioglu S. Cancer Gene Therapy. 2006 Jan; 13(1): 21-31
 
13. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. Sanlioglu AD, Dirice E, Aydin C, Erin E, Koksoy S and Sanlioglu S. BMC Cancer. 2005 25;5(1):54
 
  1. Differential PTEN protein expression profiles in superficial versus invasive bladder cancers. Koksal IT, Yasar D, Dirice E., Usta MF, Karauzum S, Luleci G, Baykara M and Sanlioglu S. Urol Int. 2005 75(2): 102-106
 
  1. The effect of cetirizine on IFN - g ve IL – 10 production in children with allergic rhinitis. Uguz A, Sanlioglu S, Yuzbey S,Coskun M,Yegin O. Turkish Journal of Pediatrics. 2005 47: 111-115
 
16. Inhibition of the NF-kB Pathway Enhances TRAIL-Mediated Apoptosis in Neuroblastoma Cells. Karacay B, Sanlioglu S, Griffith TS, Sandler A and Bonthius DJ. Cancer Gene Therapy. 2004 Oct; 11(10): 681-690.
 
17. Novel approaches to augment adeno-associated virus type-2 endocytosis and transduction. Sanlioglu AD, Karacay B, Benson PK, Engelhardt JF and Sanlioglu S. Virus Research. 2004 Aug; 104(1): 51-59.
 
18. The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. Koksal IT., Dirice E, Yasar D, Sanlioglu AD, Gulkesen KH, Ciftcioglu A., Ozes ON, Baykara M, Luleci G and Sanlioglu S. Urol Oncol. 2004 22(4): 307-312.
 
  1. Fundamental Principals of Tumor Necrosis Factor-alpha gene therapy approach and implications for patients with lung carcinoma. Sanlioglu AD, Aydin C, Bozcuk H, Terzioglu E and Sanlioglu S. Lung Cancer. 2004 44: 199-211.
 
20. Current progress in adenovirus mediated gene therapy for patients with prostate carcinoma. Sanlioglu AD, Koksal T, Baykara M, Luleci G, Karacay B, Sanlioglu S. Gene Ther Mol Biol. 2003 7: 113-133.
 
21. Genetic redox preconditioning differentially modulates AP-1 and NFkappaB responses following cardiac ischemia/reperfusion injury and protects against necrosis and apoptosis. Yang J, Marden JJ, Fan C, Sanlioglu S, Weiss RM, Ritchie TC, Davisson RL, Engelhardt JF. Molecular Therapy. 2003 Mar;7(3): 341-353
 
22. First generation adenovirus vectors shorten survival time in a murine model of sepsis. Sanlioglu, S, Doerschug K, Flaherty, DM, Wilson RL, Yarovinsky TO, Monick MM, Engelhardt JF and Hunninghake GW. J. Immunology. 2002 169: 6539-6545.
 
  1. Mitochondrial K(ATP) channel openers activate the ERK kinase by an oxidant-dependent mechanism. Samavati L, Monick MM, Sanlioglu S, Buettner GR, Oberley LW, and Hunninghake GW. Am J Physiol Cell Physiol. 2002 Jul;283(1): C273-81.
 
24. Simultaneous inhibition of Rac1 and IKK Pathways sensitizes lung cancer cells to TNFa mediated apoptosis. Sanlioglu S, Luleci G and Thomas KW. Cancer Gene Therapy. 2001 8(11): 897-905.
 
25. GPx-1 gene delivery modulates NFkB activation following diverse environmental injuries through a specific subunit of the IKK complex. Li Q, Sanlioglu S, Li S, Ritchie T, Oberley L and Engelhardt JF. Antioxidant and Redox Signaling. 2001 3(3): 415-431.
 
26. LPS induces Rac1 dependent reactive oxygen species (ROS) formation and coordinates TNFa secretion through IKK regulation of NFkB. Sanlioglu S, Williams CM, Samavati L, Butler NS, Wang G, McCray PB, Ritchie TC, Hunninghake GW, Zandi E and Engelhardt JF. JBC. 2001 Aug 276(32): 30188-30198.
 
27. Rate Limiting Steps of AAV transduction and Implications for Human Gene Therapy. Sanlioglu S, MonickMM, Luleci G, Hunninghake GW and EngelhardtJF. Review. Current Gene Therapy.  2001 June; 1(2): 137-147.
 
28. Endocytosis and Nuclear Trafficking of Adeno-Associated Virus Type-2 is Controlled by Rac1/PI3-kinase Activation. Sanlioglu S, Benson PK, Yang J, Atkinson EM, Reynolds T and Engelhardt JF. Journal of Virology. 2000 Oct; 74(19): 9184-9196 (Cover illustration)
 
29. Loss of ATM Function Enhances Recombinant Adeno-Associated Virus Transduction and Integration through Pathways Similar to UV Irradiation. Sanlioglu S, Benson P, Engelhardt JF. Virology. 2000 Mar 1; 268(1): 68-78 (Cover illustration)
 
30. Two Independent Molecular Pathways for Recombinant Adeno-Associated virus genome conversion occur after UV-C and E4orf6 augmentation of transduction. Sanlioglu S, Duan D and Engelhardt JF. Human Gene Therapy. 1999 March 1;10(4): 591-602.
 
31. Cellular Redox State Alters Recombinant Adeno-Associated Virus Transduction Through Tyrosine Phosphatase Pathways. Sanlioglu S and Engelhardt JF. Gene Therapy. 1999 6: 1427-1437.
 
32. Formation of adeno-associated virus circular genomes is differentially regulated by adenovirus E4-ORF6 and E2a gene expression. Duan D, Sharma P, Dudus L, Zhang Y, Sanlioglu S, Yan Z, Yue Y, Lester R, Yang J, Fisher KJ, Engelhardt, J.F. Journal of Virology. 1999 73(1): 161-169.
 
33. Selective disruption of "late onset" sagittal banding patterns by ectopic expression of engrailed-2 in cerebellar Purkinje cells. Baader SL, Vogel MW, Sanlioglu S, Zhang X, Oberdick J. Journal of Neuroscience. 1999 Jul 1; 19(13): 5370-5379.
 
34. Regulation of a Purkinje cell-specific promoter by homeodomain proteins: repression by engrailed-2 vs. synergistic activation by Hoxa5 and Hoxb7. Sanlioglu S, Zhang X, Baader SL, Oberdick J.  Journal of Neurobiology. 1998 Sep 15; 36(4): 559-571.
 
35. Ectopic overexpression of engrailed-2 in cerebellar Purkinje cells causes restricted cell loss and retarded external germinal layer development at lobule junctions. Sanlioglu S, Baader SL, Berrebi AS, Parker-Thornburg J, Oberdick J. Journal of Neuroscience. 1998 Mar 1; 18(5): 1763-1773.
 
36. Functional cloning of candidate genes that regulate Purkinje cell-specific gene expression. Sanlioglu-Crisman S. and Oberdick J. Progress in Brain Research. 1997 114: 3-19.
 
37. Local control of granule cell generation by cerebellar Purkinje cells. Smeyne R, Chu T, Lewin A, Bian F, Sanlioglu-Crisman S, Kunsch C, Lira SA and Oberdick J. Mol Cell Neuroscience. 1995 6: 230-251.
 
38. Structure and genetics of the partially duplicated gene RP located immediately upstream of the complement C4A and C4B genes in the HLA class III region. Shen L, Wu LC, Sanlioglu S, Chen R, Mendoza AR, Dangel A, Carroll MC, Zipf WB, Yung CY. Journal of Biological Chemistry. 1994 269(11): 8466-8476.
 
39. Isolation of Acinetobacter lwoffi from hens with septicemia Kaya O, Ates M, Erganis O, Corlu M. and SanliogluS. Journal of Veterinary Medicine. 1989 36(2): 157-158.
 
ABSTRACTS and PRESENTATIONS (International Meetings):
 
1.      High endogenous TRAIL expression level is correlated with increased cell death in human pancreas. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Balcı MK, Ömer A, Griffith TS and Sanlioglu S. Abstract. P215.XV Annual Congress of the European Society of Gene Therapy, Rotterdam, Netherlands, Human Gene Therapy. 18:(10) 994-1092 October 2007.
 
2.      Adenovirus vectors efficiently deliver TRAIL into pancreatic islets without generating cytotoxic effects.Dirice E, Sanlioglu AD, Omer A, Balci MK, Griffith TS and Sanlioglu S. Abstract. P214.XV Annual Congress of the European Society of Gene Therapy, Rotterdam, Netherlands, Human Gene Therapy. 18:(10) 994-1092 October 2007.
 
3.      Comparative analysis of TRAIL and its receptor expression profiles in synoviocytes versus peripheral lymphocytes of patients with Rheumatoid Arthritis. Bisgin A, Sanlioglu AD, Ulker M, Yazisiz V, Terzioglu E and Sanlioglu S. Abstract. P258.XV Annual Congress of the European Society of Gene Therapy, Rotterdam, Netherlands, Human Gene Therapy. 18:(10) 994-1092 October 2007.
 
4.      Expression profile of TRAIL and its receptors in breast cancer patients with invasive ductal carcinoma.Sanlioglu AD, Korcum AF, Pestereli E, Erdogan G, Karaveli S, Savas B, Griffith TS and Sanlioglu S. Abstract 2136. European Journal of Cancer. 5 (4) 225-226 September 2007.
 
5.      Testing the efficacy of substance P fragments as antitumor agents. Erin E, Korcum AF, Simsek E, Aydemir E, Sanlioglu S. 6th AFMC International Medicinal Chemistry Symposium. Drugs of the Future. Volume 32. Suppl. A. Abstract PA-45. Istanbul, Turkey, July 8-11 2007.
 
6.      A DcR2 siRNA strategy employing three different siRNA constructs in combination defeats adenovirus transferred TRAIL resistance in lung cancer cells. Aydin C., Sanlioglu AD, Karacay B, Ozbilim G, Dertsiz L, Ozbudak O, Akdis CA and Sanlioglu S. Abstract. P103. XIV Annual Congress of the European Society of Gene Therapy, Athens, Greece, November 9-12, 2006.
 
7.      Small interference RNA technology targeting DcR2 sensitized advanced prostate carcinoma cells to adenovirus delivery of TRAIL. Sanlioglu AD, Koksal IT, Karacay B and Sanlioglu S. Abstract. P140. XIV Annual Congress of the European Society of Gene Therapy, Athens, Greece, November 9-12, 2006.
 
8.      TRAIL-R4 (DcR2) receptor gene expression is correlated with high Gleason scores, PSA recurrence, and decreased survival in patients with prostate carcinoma. Koksal IT, Sanlioglu AD, Karacay B, Griffith TS and Sanlioglu S. Abstract. P141. XIV Annual Congress of the European Society of Gene Therapy, Athens, Greece, November 9-12, 2006.
 
9.      Novel gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis. Bisgin A, Sanlioglu AD, Ulker M, Yazisiz V, Tuzuner S, Terzioglu E and Sanlioglu S. Abstract. P206. XIV Annual Congress of the European Society of Gene Therapy, Athens, Greece, November 9-12, 2006.
 
10. Electroporation enhances the first generation adenovirus vector transgene delivery into pancreatic islets. Dirice E, Sanlioglu AD, Omer A, Balci MK and Sanlioglu S. Abstract. P208. XIV Annual Congress of the European Society of Gene Therapy, Athens, Greece, November 9-12, 2006.
 
11. Upnormal increase in the nuclear NF-kB activity of the rat cavernosal tissue is correlated with diabetes related erectile dysfunction syndrome. Yoldas B, Usta MF and Sanlioglu S. Abstract. P213. XIV Annual Congress of the European Society of Gene Therapy, Athens, Greece, November 9-12, 2006.
 
12. A DcR2 siRNA approach defeats TRAIL resistance in lung cancer cells. Aydin C, Sanlioglu AD, Ozbudak O, Dertsiz L Ozbilim G, Akdis CA and Sanlioglu S. Abstract. P213. 31st FEBS Congress, Istanbul, Turkey, June 24-29 2006.
 
13. Differential expression of TRAIL and its receptors in patients with prostate carcinoma. Sanlioglu AD, Koksal IT, Ciftcioglu A, Baykara M, Luleci G, and Sanlioglu S. Abstract. P212. 31st FEBS Congress, Istanbul, Turkey, June 24-29 2006.
 
14. Adenovirus delivery of TRAIL effectively destroys synoviocytes of patients with rheumatoid arthritis. Bisgin A, Sanlioglu AD, Ulker M, Tuzuner S, Terzioglu E and Sanlioglu S. Abstract. P214. 31st FEBS Congress, Istanbul, Turkey, June 24-29 2006.
 
15. Adenovirus mediated TRAIL gene delivery as a model for the treatment of patients with diabetes. Dirice E, Sanlioglu AD, Omer A, Balci MK, Terzioglu E and Sanlioglu S. Abstract. P482. 31st FEBS Congress, Istanbul, Turkey, June 24-29 2006.
 
 
17. Surface TRAIL decoy receptor-4 expression constitutes a resistance to adenovirus delivery of TRAIL in MCF7 breast cancer cells. Sanlioglu AD, Dirice E, Aydin C, Erin E, Koksoy S and Sanlioglu S. Abstract, P015. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
 
  1. TRAIL ligand and receptor expressions are differentially upregulated in prostate carcinoma patients: a significant issue for gene therapy of advanced prostate cancer. Sanlioglu AD, Koksal IT, Ciftcioglu A, Bassorgun IC, Baykara M, Luleci G, and Sanlioglu S. Abstract. P022. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
 
  1. Decoy receptor gene expression as a chief mechanism to govern TRAIL resistance in advanced prostate carcinoma. Sanlioglu AD, Koksal IT, Karacay B, Baykara M, Luleci G, and Sanlioglu S. Abstract. P023. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
 
  1. Efficient adenovirus mediated TRAIL gene delivery into pancreatic islets as a model for the treatment of patients with type 1 diabetes. Dirice E, Sanlioglu AD, Omer A, Balci MK and Sanlioglu S. Abstract. P074. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
 
  1. Adenovirus delivery of TRAIL effectively destroys synovial fibroblasts of patients with rheumatoid arthritis. Bisgin A, Sanlioglu AD, Ulker M, Tuzuner S, Terzioglu E and Sanlioglu S. Abstract. P075. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
 
  1. A CTLA-4 exon 1+49 A/A genotype is linked to the clinical progression of systemic lupus erythematosus in patients. Ulker M, Terzioglu E, Yazisiz V and Sanlioglu S. Abstract. P076. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
 
  1. Testing the efficacy of an adenovirus mediated TRAIL gene delivery for the treatment of patients with osteoarthritis. Bisgin A, Sanlioglu AD, Ulker M, Tuzuner S, Terzioglu E and Sanlioglu S. Abstract. P078. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
 
  1. A DcR2 siRNA approach overcomes TRAIL resistance in A549 lung cancer cells. Aydin C, Sanlioglu AD, Ozbudak O, Dertsiz L and Sanlioglu S. Abstract. P172. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
 
  1. Adenovirus mediated NF-kB inhibiting strategies for the treatment of patients with type 1 diabetes. Burcak Y and Sanlioglu S. Abstract. P088. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
 
  1. Testing the efficacy of a novel adenovirus mediated TRAIL gene therapy approach for the treatment of patients with Type 1 Diabetes. Dirice E. Sanlioglu AD, Koksoy S, Balci MK, Omer A and Sanlioglu S. Abstract. P160. Advances in Molecular Medicine, Istanbul, 2005.
 
  1. Adenovirus mediated TRAIL gene delivery as a gene therapy model for patients with advanced prostate carcinoma. Sanlioglu AD, Koksal IT, Karacay B, Baykara M, Luleci G and Sanlioglu S. L14. Advances in Molecular Medicine, Istanbul, 2005.
 
  1. A novel gene therapy model for patients with Rheumatoid Arthritis. Bisgin A, Sanlioglu AD, Ulker M, Dirice E, Tuzuner S, Koksoy S, Terzioglu E and Sanlioglu S. Abstract. P161. Advances in Molecular Medicine, Istanbul, 2005.
 
  1. Adenovirus mediated IKKbKA expression sensitized advanced prostate carcinoma cells to TRAIL-Mediated apoptosis in spite of decoy receptor gene expression. Sanlioglu AD, Koksal IT, Baykara M, Luleci G, Karacay B and Sanlioglu S. Abstract. P165. Advances in Molecular Medicine, Istanbul, 2005.
 
  1. A novel death ligand mediated gene therapy approach for patients with lung cancer. Aydin C, Sanlioglu AD, Dirice E, Dertsiz L, Ozbudak O and Sanlioglu S. Abstract. P162. Advances in Molecular Medicine, Istanbul, 2005.
 
  1. Adenovirus delivery of IKKbKA to liver improves survival in a murine model of endotoxic shock. Yoldas B, Engelhardt JF and Sanlioglu S. Abstract. P167. Advances in Molecular Medicine, Istanbul, 2005.
 
  1. Surface TRAIL Receptor-4 expression correlates with TRAIL resistance in breast cancer cells. Sanlioglu AD, Dirice E, Aydin C, Erin E, Koksoy S and Sanlioglu S. Abstract. P164. Advances in Molecular Medicine, Istanbul, 2005.
 
  1. Fundamental principals of Tumor Necrosis Factor-alpha gene therapy approach for patients with lung carcinoma. AD Sanlioglu, C Aydin, H Bozcuk, E Terzioglu and S Sanlioglu Abstract. Or4. 12th Annual Congress of European Society of Gene Therapy, Tampere, Finland 2004
 
  1. Anti HIV drug PDTC genetoxic agents synergistically activate Adeno Associated Virus Type-2 endocytosis and transduction. AD Sanlioglu, B Karacay, PK Benson, JF Engelhardt and S Sanlioglu Abstract. P56. 12th Annual Congress of European Society of Gene Therapy, Tampere, Finland, 2004
 
  1. Advanced prostate cancer cells display differential NF-kB activation pattern which is the primary determinant of TRAIL resistance. AD Sanlioglu, IT Koksal, M Baykara, G Luleci, B Karacay and S Sanlioglu Abstract, P19. 12th Annual Congress of European Society of Gene Therapy, Tampere, Finland, 2004
 
  1. Resistance to Adenovirus mediated TRAIL gene therapy in breast cancer cells is eliminated by the expression of dominant negative IKKb. AD Sanlioglu, E Dirice and Salih Sanlioglu. Abstract. P20. 12th Annual Congress of European Society of Gene Therapy Tampere, Finland, 2004
 
  1. Therapeutic effect of recombinant adenovirus mediated TRAIL gene therapy method in Lung Cancer. C Aydin, AD Sanlioglu, E Dirice and Salih Sanlioglu. Abstract. P22. 12th Annual Congress of European Society of Gene Therapy, Tampere, Finland, 2004
 
  1. An in vivo model for IKK modulation of adenovirus delivery of TNF-alpha mediated gene therapy for patients with lung carcinoma. Sanlioglu S. Abstract. P38. British Association for Cancer Research (BACR) Conference on Stem cells and Telomerase. Salamis Bay, NC, 2004
 
39. Adenovirus mediated NF-kB inhibiting gene therapy for breaking down TRAIL resistance observed in advanced prostate carcinoma. Sanlioglu AD, Koksal IT, Baykara M, Luleci G, Karacay B and Sanlioglu S. Abstract. P234. 11th Annual Congress of European Society of Gene Therapy, Edinburgh, UK 2003
 
40. Gene Expression of a Dominant Negative IKK-beta Mutant in the Liver Improves Survival in a Murine Model of Endotoxic Shock. Sanlioglu S, Williams CM,Sanlioglu AD and Engelhardt JF. Abstract. P269. 11th Annual Congress of European Society of Gene Therapy, Edinburgh, UK 2003
 
  1. TRAIL-Mediated Apoptosis of Neuroblastoma cells is Enhanced by Simultaneous Inhibition of the NF-kB Pathway. Bahri Karacay, Salih Sanlioglu, Thomas S. Griffith, Anthony Sandler, Nicholas J. Pantazis and Daniel J. Bonthius, Neuroscience Meeting, Abstracts, 2003
 
  1. PTEN expression inversely correlates with high Gleason scores and serum PSA levels which are the major prognostic indicators of the advanced prostate carcinoma. Koksal I.T., Dirice E., Yasar D., Ozes O.N., Baykara M., Luleci G., and Sanlioglu S. Abstract. P31. Innovations in the Diagnosis and Treatment of Prostate Cancer, 6th Seminar of the International Cooperative Study of Diagnostic Ultrasound and Prostate Cancer, Antalya-Turkey, 2002
 
  1. PTEN as a diagnostic tool for the prognosis of prostate carcinomas. Dirice E., Koksal I.T., Yasar D., Ozes O.N., Baykara M., Luleci G., and Sanlioglu S. Abstract. International Journal of Cancer, P745 18th UICC International Cancer Congress. Oslo-Norway, 2002
 
44. Abrogation of PTEN expression is crucial for the progression of bladder carcinomas. Yasar D., Koksal T., Dirice E., Ozes O.N., Baykara M., Luleci G., and Sanlioglu S. Abstract. International Journal of Cancer, P714 18th UICC International Cancer Congress. Oslo-Norway, 2002
 
45. A new treatment modality for lung cancer; Differential regulation of Rac1 and IKK pathways sensitizes lung cancer cells to TNF mediated apoptosis. Sanlioglu S., Luleci G. and Thomas K.W. Abstract, Journal of Gene Medicine. P149. 9th Annual Meeting of European Society of Gene Therapy, Antalya, Turkey, 2001
 
  1. GPx-1 regulated intracellular hydrogen peroxide level specifically modulates IKK-alpha activity. Li Q, Sanlioglu S, Li SJ, Ritchie T, Oberley L, Engelhardt JF. Molecular Biology of the Cell, 12: 1947 Suppl. S NOV 2001
 
47. Novel approaches to induce Adeno-associated virus type-2 endocytosis through synergistic activation of Rac1 and PI3K pathways. Sanlioglu S., Benson P., Ritchie T. and Engelhardt J.F. Abstract522, Molecular Therapy. 4th Annual Meeting of American Society of Gene Therapy, 2001
 
48. Regulation of Adeno-Associated Virus Type-2 Endocytosis and Nuclear Trafficking by Rac1/PI3-kinase Pathways. Sanlioglu S., Benson P.K. Yang J., Atkinson E.M., Reynolds T. and Engelhardt J.F. Abstract 348, Molecular Therapy. 3rd Annual Meeting of American Society of Gene Therapy, 2000
 
49. ATM gene defect increases the efficiency of adeno-associated virus transductions. Sanlioglu S., and Engelhardt J. Abstract 596, Molecular Therapy. 2nd Annual Meeting of American Society for Gene Therapy, 1999.
 
50. UV radiation increases the abundance of AAV circular but not replication form intermediates. Sanlioglu S, and Engelhardt J. Abstract 227, Pediatric Pulmonology, 1998.
 
51. UV radiation and reactive oxygen species augment rAAV transduction through NFkB independent pathways. Sanlioglu S., and Engelhardt J. Abstract 226, Pediatric Pulmonology, 1998.
 
52. Effect of ectopic En-2 expression in Purkinje cells on development of the cerebellum. Sanlioglu-Crisman S. and Oberdick J. Abstract 121.2, Society for Neuroscience, 1996.
 
53. Activation of a Purkinje cell specific gene by homeobox proteins. Sanlioglu-Crisman S. and Oberdick J. Abstract 2000. Molecular Biology of the Cell, 1995.
 
 
ABSTRACTS and PRESENTATIONS (National meetings):
 
1.      In vivo fluorescent imaging of adenovirus delivery of reporter gene expression for allogeneic islet transplantation. Kahraman S, Dirice E, Sanlioglu AD, Balci MK, Omer A, Griffith TS and Sanlioglu S. 3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, Abstract No 11, Istanbul, 29 Mayis-1 Haziran 2008.
 
  1. Adenovirus-mediated human TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets provides prolonged normoglycemia in STZ-induced diabetic rats. Dirice E, Sanlioglu AD, Kahraman S, Omer A, Balci MK, Griffith TS and Sanlioglu S. 3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, Abstract No 10, Istanbul, 29 Mayis-1 Haziran 2008.
 
  1. The success of rat islet isolation mainly relies on complete pancreas inflation. Kahraman S, Dirice E, Sanlioglu AD, Yoldas B, Balci MK, Omer A, Griffith TS and Sanlioglu S. 3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, Abstract No 4, Istanbul, 29 Mayis-1 Haziran 2008.
 
  1. Gene therapy application scenarios to prolong islet-graft survival in patients with type 1 diabetes: Kahraman S, Dirice E, Sanlioglu AD, Balci MK, Omer A, Griffith TS and Sanlioglu S. 3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, Abstract, Istanbul, 29 Mayis-1 Haziran 2008.
 
  1. Pancreatic ductal adenocarcinoma (PDAC) patients displayed high levels of TRAIL death receptor-4 (DR4) and decoy receptor-2 (DCR2) expressions in connection with significant amount of cell death. Sanlioglu AD, Dirice E, Elpek O, Korcum A, Ozdogan M, Suleymanlar I, Balci MK, Griffith TS, Sanlioglu S. 3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, Abstract No 5, Istanbul, 29 Mayis-1 Haziran 2008.
 
  1. Gene therapy mediated apoptosis inducing approaches employing Ad5hTRAIL and a DCR2 siRNA strategy in lung cancer patients. Aydin C, Sanlioglu AD, Karacay B, Ozbilim G, Dertsiz L, Ozbudak O, Akdis CA, Sanlioglu S. 3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, Abstract No 3, Istanbul, 29 Mayis-1 Haziran 2008.
 
  1. Comparative analysis of TRAIL and its receptor expression profiles in synoviocytes versus peripheral lymphocytes of patients with rheumatoid arthritis. Bisgin A, Sanlioglu AD, Yazisiz V, Terzioglu E, Sanlioglu S. 3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, Abstract No 14, Istanbul, 29 Mayis-1 Haziran 2008.
 
  1. Pankreatik adaciklarda adenoviral vektor aracili transgen sentez suresinin in vivo olarak CCCD kamera ile goruntulenmesi. Kahraman S, Dirice E, Sanlioglu AD, Balci MK, Omer A, Griffith TS and Sanlioglu S. 44. Ulusal Diyabet Kongresi, Abstract, Antalya, 28 Mayis-1 Haziran 2008.
 
  1. Pankreatik adaciklara adenovirus aracili insan TRAIL geni (Ad5hTRAIL)aktarimi STZ induklemeli diyabetik sicanlarda uzun sureli normoglisemi saglar. Dirice E, Sanlioglu AD, Kahraman S, Omer A, Balci MK, Griffith TS and Sanlioglu S. 44. Ulusal Diyabet Kongresi, Abstract, Antalya, 28 Mayis-1 Haziran 2008.
 
  1. Tip 1 diyabet hastalarinda gerceklestirilen adacik naklinde graft sagkalimini uzatabilecek gen tedavi senaryolari: Kahraman S, Dirice E, Sanlioglu AD, Balci MK, Omer A, Griffith TS and Sanlioglu S. 44. Ulusal Diyabet Kongresi, Abstract, Antalya, 28 Mayis-1 Haziran 2008.
 
  1. Pankreatik adacik izolasyon basarisini artirmaya yonelik yapilan deneysel bir calisma: Kahraman S, Dirice E, Sanlioglu AD, Yoldas B, Balci MK, Omer A, Griffith TS and Sanlioglu S. 44. Ulusal Diyabet Kongresi, Abstract, Antalya, 28 Mayis-1 Haziran 2008.
 
  1. Pankreatik duktal adenokarsinomali hastalarda trail olum reseptoru-4 (DR4) ve yalanci reseptor-2’nin (DCR2) ekspresyonlarindaki artis, artan hucre olumleri ile iliskilidir. Sanlioglu AD, Dirice E, Elpek O, Korcum A, Ozdogan M, Suleymanlar I, Balci MK, Griffith TS, Sanlioglu S. 44. Ulusal Diyabet Kongresi, Abstract, Antalya, 28 Mayis-1 Haziran 2008.
 
  1. TRAILING from molecular diagnostics to prostate cancer gene therapy. Sanlioglu AD, Koksal IT, Karacay B, Ciftcioglu MA, Baykara M, Luleci G, Griffith TS and Sanlioglu S. XIX Ulusal İmmunoloji Kongresi, Abstract, Antalya, 21-24 Kasım 2007.
 
  1. Yokluğu Tip 1 diyabetle ilişkilendirilmis TNF-Related Apoptosis Inducing Ligand (TRAIL) ölümcül ve yalancı reseptorlerinin normal insan pankreasindaki sentez profili. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Balcı MK, Ömer A, Griffith TS and Sanlioglu S. 43. Ulusal Diyabet Kongresi, Abstract, PS54, Antalya, 9-13 Mayıs 2007.
 
  1. Tip 1 diyabetli hastalarda kullanılacak etkin bir tedavi modelinin geliştirilmesi maksadıyla pankreatik adacıklara adenovirus aracılı TRAİL geni aktarımı. Dirice E, Sanlioglu AD, Ömer A, Balcı MK, Griffith TS and Sanlioglu S. 43. Ulusal Diyabet Kongresi, Abstract, PS51, Antalya, 9-13 Mayıs 2007.
 
  1. Tip 1 diyabette ölümcül ligant aracılı gen tedavi modelinin moleküler etki mekanizması. Sanlioglu AD, Dirice E, Ömer A, Terzioğlu E, Sarı R, Balcı MK, Griffith TS and Sanlioglu S. 43. Ulusal Diyabet Kongresi, Abstract, Antalya, 9-13 Mayıs 2007.
 
  1. Tip 1 diyabet gelişiminde rol alan TNF-Related Apoptosis Inducing Ligand (TRAIL) ölümcül ve yalancı reseptörlerinin normal insan pankreasindaki sentez profili ve artan apoptozis ile korelasyonu. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Balcı MK, Ömer A, Griffith TS and Sanlioglu S. X. Tıbbi Biyoloji ve Genetik Kongresi, Abstract, P112, Antalya, 6-9 Eylül 2007.
 
  1. Adenoviral vektörler sitotoksik etki oluşturmadan pankreatik adacıklara etkin TRAIL gen aktarımı sağlar. Dirice E, Sanlioglu AD, Ömer A, Balcı MK, Griffith TS and Sanlioglu S. X. Tıbbi Biyoloji ve Genetik Kongresi, Abstract, P134, Antalya, 6-9 Eylül 2007.
 
  1. Adenovirus aracılı TRAİL transferi osteoartritli hastalardan izole edilmiş normalde apoptoza dirençli sinovyal fibroblastları yok etti. Bisgin A, Sanlioglu AD, Tuzüner S, Terzioglu E and Sanlioglu S. X. Tıbbi Biyoloji ve Genetik Kongresi, Abstract, P153, Antalya, 6-9 Eylül 2007.
 
  1. Potential therapeutic efficacy of adenovirus delivery of TRAIL for patients with prostate carcinoma. Sanlioglu AD, Koksal IT, Karacay B, Ciftcioglu MA, Baykara M, Luleci G, Griffith TS and Sanlioglu S. X. Tıbbi Biyoloji ve Genetik Kongresi, Abstract K11, Antalya, 6-9 Eylül 2007.
 
  1. Adenovirus aracılı ölümcül ligand transferinin gen tedavisindeki yeri. Sanlioglu S. IX. Ulusal Tıbbi Biyoloji Kongresi, Abstract K19, Manisa, 2005.
 
  1. İleri evre prostat karsinomada yalancı reseptör gen ekspresyonu TRAİL dirençliliğinin ortaya çıkmasında önemli bir faktördür. Sanlioglu AD, Koksal IT, Karacay B, Baykara M, Luleci G, Griffith TS and Sanlioglu S. IX. Ulusal Tıbbi Biyoloji Kongresi, Abstract P12, Manisa, 2005.
 
  1. Adenovirus aracılı TRAİL gen transferinin romatoid artritli hastalıklardaki terapötik etkisi. Bisgin A, Sanlioglu AD, Ulker M, Tuzüner S, Terzioglu E and Sanlioglu S. IX. Ulusal Tıbbi Biyoloji Kongresi, Abstract P41, Manisa, 2005.
 
  1. Tip 1 diyabetli hastalar için geliştirilen pankreatik adacık transplantasyonunda adenovirus aracılı TRAİL gen transferinin etkinliği. Dirice E, Sanlioglu AD, Ömer A, Balcı MK, and Sanlioglu S. IX. Ulusal Tıbbi Biyoloji Kongresi, Abstract P66, Manisa, 2005.
 
  1. DcR2 siRNA yaklaşımı A549 akciğer kanser hücrelerini adenovirus aracılı TRAİL transferine duyarlı kılar. Aydın C, Sanlioglu AD, Özbudak Ö, Dertsiz L and Sanlioglu S. IX. Ulusal Tıbbi Biyoloji Kongresi, Abstract AG05, Manisa, 2005.
 
  1. The implication of adenovirus mediated death ligand gene delivery for human gene therapy. Sanlioglu AD, Koksal IT, Baykara M, Luleci G, and Sanlioglu S. XVIII. Ulusal İmmunoloji Kongresi, Abstract, Antalya, 2005.
 
  1. Current Progress in Cancer Gene Therapy. Sanlioglu S. XIX Ulusal Biyokimya Kongresi, Abstract K05, Antalya, 2005.
 
  1. Hücre içi anti-apoptotik yolun bloke edilmesi meme kanserini adenovirus aracılı TRAİL gen tedavi metoduna karşı duyarlı hale getirdi. Sanlioglu AD, Dirice E, and Sanlioglu S. 1. Ulusal Klinik Pratikde Kök Hücre ve Gen Tedavisi Kongresi, Abstract P127, İstanbul, 2004.
 
  1. Akciğer kanserinde recombinant adenovirus aracılı TRAİL gen tedavi metodunun terapötik etkisi. Aydın C, Sanlioglu AD, Dirice E, and Sanlioglu S. 1. Ulusal Klinik Pratikde Kök Hücre ve Gen Tedavisi Kongresi, Abstract P128, İstanbul, 2004.
 
  1. An in vivo model for IKK modulation of adenovirus delivery of TNF-alpha mediated gene therapy for patients with lung carcinoma. Sanlioglu S. 1. Ulusal Klinik Pratikde Kök Hücre ve Gen Tedavisi Kongresi, Abstract P135, İstanbul, 2004.
 
  1. Akciğer kanserinde yeni bir adenovirus aracılı TNF-alpha gen tedavi metodu. Sanlioglu S. VI. Ulusal Prenatal Tanı ve Tıbbi Genetik Kongresi, Abstract, KSB 08, Antalya, 2004.
 
  1. İleri ever prostat kanserinde NFkB yolunun bloke edilmesi TRAİL dirençliliğini kırar. Sanlioglu AD, Koksal IT, Baykara M, Luleci G, Karacay B and Sanlioglu S. VI. Ulusal Prenatal Tanı ve Tıbbi Genetik Kongresi, Abstract, MP 27, Antalya, 2004.
 
  1. Karaciğerde adenovirus aracılı dominant negative IKK beta mutandının gen sentezi endotoksik şoktan hayatta kalma süresini arttırır. Sanlioglu S and Engelhardt JF. VI. Ulusal Prenatal Tanı ve Tıbbi Genetik Kongresi, Abstract, MP 47, Antalya, 2004.
 
  1. İleri ever meme kanserinin adenovirus aracılı TRAİL gen tedavi metoduna duyarlılaştırma yöntemleri. Sanlioglu AD, Dirice E, and Sanlioglu S. VI. Ulusal Prenatal Tanı ve Tıbbi Genetik Kongresi, Abstract, KP 04, Antalya, 2004.
 
  1. PTEN ekspresyon düzeyinin mesane kanseri gelişimindeki rolü. Yasar D, Koksal IT, Dirice E, Özeş ON, Baykara M, Karauzum SB, Luleci G, and Sanlioglu S. XV. Ulusal Kanser Kongresi, Abstract, P558, Antalya, 2003.
 
  1. Prostat kanserli olgularda PTEN ekspresyonunun prognostic değeri. Dirice E Koksal IT, , Yasar D, Özeş ON, Baykara M, Luleci G, and Sanlioglu S. XV. Ulusal Kanser Kongresi, Abstract, P559, Antalya, 2003.
 
  1. Gen tedavisinde güncel gelişmeler. Sanlioglu S and Sanlioglu AD. 8. Ulusal Tıbbi Biyoloji Kongresi, Abstract, Adana, 2003.
 
  1. Adenovirus aracılı TRAİL geni aktarımının prostat karsinomanın farklı evreleri üzerindeki etkinliği ve prostat kanserli hastalarda TRAİLe olan direnci kırmak için yeni gen tedavi metotlarının geliştirilmesi. Sanlioglu AD, Koksal IT, Baykara M, Luleci G, and Sanlioglu S. 8. Ulusal Tıbbi Biyoloji Kongresi, Abstract ÖS-3, Adana, 2003.
 
  1. Mesane kanser gelişiminde PTENin prognostik değerinin belirlenmesi. Yasar D, Koksal IT, Dirice E, Karauzum SB, Çifçioğlu A, Baykara M, Özeş ON, Luleci G, and Sanlioglu S. 8. Ulusal Tıbbi Biyoloji Kongresi. Abstract SS-4, Adana, 2003.
 
  1. PTENin Gleson skoru ve PSAya kıyasla prostat kanserindeki prognostik değerinin belirlenmesi. Dirice E Koksal IT, , Yasar D, Sanlioglu AD, Çifçioğlu A, Gülkesen KH, Özeş ON, Baykara M, Luleci G, and Sanlioglu S. 8. Ulusal Tıbbi Biyoloji Kongresi, Abstract SS-5, Adana, 2003.
 
AWARDS:
·         Akdeniz University Scientific Achievement Award, 2007
 
·         Altan Gunalp Medical Research Award, 1st place 2007
 
·         43rd National Diabetes Congress Poster Award. 2nd place, 2007
 
·         European Union Framework Program Project Proposal Submission Encouragement Award, 2005
 
·         Abbott Rheumatoid Arthritis Research Award, 2nd place, 2005
 
·         TUBITAK Investigator Career Award, 2004
 
  • Schering-German Urooncology Award, 1st place. 2004. The testing of a novel treatment modality in order to breakdown TRAIL resistance in prostate cancer.
 
  • Schering-German Urooncology Award, 3rd place. 2003. The assessment of PTEN as a prognostic marker in combination with Gleason scoring and serum PSA in order to evaluate the progression of prostate carcinoma.
 
·         Altan Gunalp Medical Research Award, 1st place 2003
 
·         Highest Caliber in Medical Research, University of Iowa, College of Medicine 2000
 
 
·         National Research Service Award, U.S. National Institute of Health, Bethesda, Maryland 1998 
 
 
·         Excellence in Scientific Presentation, 18th annual meeting of Graduate Student Forum, ICSABER Society of the Ohio State University, Columbus, Ohio
 
·         Excellence in Scientific Presentation, Children’s Hospital Research Foundation, The Ohio State University, Columbus, Ohio, 1992
 
MEMBERSHIP to PROFESSIONAL SOCIETIES:
 
·         Member of the European Society of Gene Therapy 2002 to current
 
·         Member of the American Society of Gene Therapy 1998-2001
 
·         Member of the Society for Neuroscience 1994-1997
 
INTERNATIONAL GRANT REVIEWER EXPERTISE:
 
·         European Union Framework Program 6 (2002-2006)
 
·         American Association for Cancer Research
 
·         International Cancer Technology Transfer Fellowships (ICRETT)
 
·         Translational Cancer Research Fellowships (TCRF)
 
REFEREED JOURNALS
 
  • Journal of Urology
 
  • Nature Clinical Practice Oncology
 
  • Cancer Letters
 
  • Journal of Gene Medicine
 
  • BMC Cancer
 
  • Expert Review of Dermatology
 
  • Cancer Detection and Prevention
 
  • Journal of Pharmacy and Pharmacology
 
JOURNAL EDITORIAL BOARD EXPERIENCE
 
  • Editorial advisory board on recent patents on anti-infective drug discovery
 
  • Editorial advisory board on advances in molecular biology
 
 
TRAINED MEDICAL FELLOWS AND GRADUATE STUDENTS
  • Peter K. Benson MD (1999-2001)
  • Carl M. Williams MD (1999-2001)
  • Ahter Dilsad Sanlioglu PhD (2001-2005)
  • Burcak Yoldas PhD (2004-2008)
  • Atil Bisgin MD, PhD (Pending) (2003-Current)
  • Ercument Dirice MS (2001-2003) ,  PhD (Pending) (2004-Current)
  • Duygu Yasar MS (2001-2003)
  • Cigdem Aydin MS (2002-2004), PhD (Pending) (2005-Current)
  • Sevim Kahraman MS (Pending) (2006-Current)
   Copyright 2008 by Salih Sanlioglu VMD, PhD    Terms Of Use    Privacy Statement